Merck KGaA, Pfizer drug fails to meet endpoints in gastric cancer trial

Merck KGaA and Pfizer said Friday that a late-stage clinical trial testing Bavencio as a first-line maintenance treatment for patients with certain forms of gastric cancer failed to meet the study's primary endpoints for survival.